Activation of mTORC1 in B Lymphocytes Promotes Osteoclast Formation via Regulation of β-Catenin and RANKL/OPG
- PMID: 26825871
- DOI: 10.1002/jbmr.2800
Activation of mTORC1 in B Lymphocytes Promotes Osteoclast Formation via Regulation of β-Catenin and RANKL/OPG
Abstract
The cytokine receptor activator of nuclear factor-κB ligand (RANKL) induces osteoclast formation from monocyte/macrophage lineage cells. However, the mechanisms by which RANKL expression is controlled in cells that support osteoclast differentiation are still unclear. We show that deletion of TSC1 (tuberous sclerosis complex 1) in murine B cells causes constitutive activation of mechanistic target of rapamycin complex 1 (mTORC1) and stimulates RANKL but represses osteoprotegerin (OPG) expression and subsequently promotes osteoclast formation and causes osteoporosis in mice. Furthermore, the regulation of RANKL/OPG and stimulation of osteoclastogenesis by mTORC1 was confirmed in a variety of RANKL-expressing cells and in vivo. Mechanistically, mTORC1 controls RANKL/OPG expression through negative feedback inactivation of Akt, destabilization of β-catenin mRNA, and downregulation of β-catenin. Our findings demonstrate that mTORC1 activation-stimulated RANKL expression in B cells is sufficient to induce bone loss and osteoporosis. The study also established a link between mTORC1 and the RANKL/OPG axis via negative regulation of β-catenin. © 2016 American Society for Bone and Mineral Research.
Keywords: B LYMPHOCYTE; OSTEOCLAST FORMATION; RANKL (RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-κB LIGAND); mTORC1 (MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1); β-CATENIN.
© 2016 American Society for Bone and Mineral Research.
Similar articles
-
Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.J Bone Miner Res. 2005 Sep;20(9):1659-68. doi: 10.1359/JBMR.050503. Epub 2005 May 2. J Bone Miner Res. 2005. PMID: 16059637
-
Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).Mol Med Rep. 2015 May;11(5):3212-8. doi: 10.3892/mmr.2015.3152. Epub 2015 Jan 7. Mol Med Rep. 2015. PMID: 25572286 Review.
-
The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells.Clin Exp Rheumatol. 2008 Mar-Apr;26(2):295-304. Clin Exp Rheumatol. 2008. PMID: 18565252 Free PMC article.
-
Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.Biochem Pharmacol. 2013 Sep 15;86(6):782-90. doi: 10.1016/j.bcp.2013.07.015. Epub 2013 Aug 6. Biochem Pharmacol. 2013. PMID: 23928189
-
Osteoclast differentiation by RANKL and OPG signaling pathways.J Bone Miner Metab. 2021 Jan;39(1):19-26. doi: 10.1007/s00774-020-01162-6. Epub 2020 Oct 20. J Bone Miner Metab. 2021. PMID: 33079279 Review.
Cited by
-
N6-Methyladenosine Modification of ANLN Enhances Hepatocellular Carcinoma Bone Metastasis.Int J Biol Sci. 2023 Jan 22;19(4):1009-1023. doi: 10.7150/ijbs.73570. eCollection 2023. Int J Biol Sci. 2023. PMID: 36923927 Free PMC article.
-
Potential of natural medicines for treatment of osteoporosis: a narrative review.J Tradit Chin Med. 2023 Feb;43(1):198-204. doi: 10.19852/j.cnki.jtcm.20221108.003. J Tradit Chin Med. 2023. PMID: 36640013 Free PMC article. Review.
-
Gut microbiota: an overlooked factor that plays a significant role in osteoporosis.J Int Med Res. 2019 Sep;47(9):4095-4103. doi: 10.1177/0300060519860027. Epub 2019 Aug 22. J Int Med Res. 2019. PMID: 31436117 Free PMC article. Review.
-
Interactions of B-lymphocytes and bone cells in health and disease.Bone. 2023 Mar;168:116296. doi: 10.1016/j.bone.2021.116296. Epub 2021 Dec 21. Bone. 2023. PMID: 34942359 Free PMC article. Review.
-
Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in Mice.Front Immunol. 2020 Oct 19;11:561294. doi: 10.3389/fimmu.2020.561294. eCollection 2020. Front Immunol. 2020. PMID: 33193330 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials